CN Patent

CN116942629A — 药物剂型

Assigned to Novartis AG · Expires 2023-10-27 · 3y expired

What this patent protects

本发明关于固体药物剂型，包含原料药3‑(2,6‑二氯‑3,5‑二甲氧基‑苯基)‑1‑{6‑[4‑(4‑乙基‑哌嗪‑1‑基)‑苯胺基]‑嘧啶‑4‑基}‑1‑甲基‑脲或其任何药学上可接受的盐。本发明进一步关于制造这些固体药物剂型的方法。

USPTO Abstract

本发明关于固体药物剂型，包含原料药3‑(2,6‑二氯‑3,5‑二甲氧基‑苯基)‑1‑{6‑[4‑(4‑乙基‑哌嗪‑1‑基)‑苯胺基]‑嘧啶‑4‑基}‑1‑甲基‑脲或其任何药学上可接受的盐。本发明进一步关于制造这些固体药物剂型的方法。

Drugs covered by this patent

infigratinib-phosphate (INFIGRATINIB PHOSPHATE)

Patent Metadata

Patent number: CN116942629A
Jurisdiction: CN
Classification: —
Expires: 2023-10-27
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.